OMER: EMA Rejects Narsoplimab
The European Medicines Agency's Human Medicines Committee issues a negative opinion for Omeros Corp.'s narsoplimab for stem cell transplant-associated thrombotic microangiopathy
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.